Orforglipron
Worth trying, BioHarmony verdict
BioHarmony score 5.8 out of 10
Orforglipron (Foundayo) is the first FDA-approved non-peptide oral GLP-1 pill, cleared for obesity in April 2026. It cut body weight about 11.2 percent at 72 weeks in the ATTAIN-1 Phase 3 trial, less than the injectables but with once-daily oral convenience and no food or water restrictions.
Read full reportWhat is Orforglipron?
Orforglipron, sold as Foundayo, is the first non-peptide GLP-1 receptor agonist you can swallow as a daily pill, and that one fact is the whole reason it matters. Every other GLP-1 drug that works well, semaglutide and tirzepatide, is a peptide that stomach enzymes would shred, so it has to be injected or, in oral semaglutide's case, wrapped in a fussy absorption trick. Orforglipron is a small molecule. Enzymes leave it alone, it absorbs at roughly 79 percent, and you take it any time of day with or without food.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
Safety watch-outs
- Severe, persistent abdominal pain, possibly radiating to the back (possible pancreatitis): stop and seek care immediately.
- A lump or swelling in the neck, hoarseness, or trouble swallowing (thyroid warning): stop and consult a clinician.
- Personal or family history of medullary thyroid cancer or MEN2: do not use.
- Repeated vomiting or signs of dehydration during titration: pause and reassess the dose with a clinician.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (2)
Attributed viewpoints, separate from primary research.
- Oral GLP-1s Are Here Deep Dive on Orforglipron Hunter Williams,
- Orforglipron (LY3502970): Benefits, Dosing, Side Effects, & More Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
Lilly reports that FDA approved orforglipron as Foundayo in April 2026 for chronic weight management in certain adults.
Primary sources
- Foundayo (orforglipron) prescribing information U.S. Food and Drug Administration,
- FDA approves Lilly's Foundayo (orforglipron) Eli Lilly and Company,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.